Why LivaNova Is Unloading Its CRM Business

LivaNova, formerly known as Sorin Group, has decided to get out of the cardiac rhythm management (CRM) business and shift more focus to its areas of strength.  The London-based company plans to sell its CRM business to Shanghai-based MicroPort for $190 million in cash. The business, which makes high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers, generated about $249 million in net sales in the fiscal year 2016. The business has roughly 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. The company said in September it was reviewing strategic options for its CRM business, including a potential divestiture. LivaNova and MicroPort founded a China-based joint venture called MicroPort Sorin CRM in 2014. The joint venture has achieved many milestones in the development, manufacture, and promotion of CRM products for the China market, LivaNova said. MicroPort Sorin CRM recently received approval from the China Food and Drug Administration for its Rega pacemaker family, the smallest sized pacemakers available on the Chinese market. LivaNova CEO Damien McDonald said the sale will enable the company to focus on its areas of strength, which includes its cardiac surgery and neuromodulation businesses. "With this divestiture, we are building the right foundation," he said. "We are focusing our portfolio on businesses that contribute to our growth and drive...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Medical Device Business Source Type: news

Related Links:

Authors: Kumanomido J, Ohe M, Shibata R, Hattori Y, Ishizaki Y, Ito S, Nohara Y, Takahashi J, Hori K, Obuchi A, Ohtsuka M, Fukumoto Y Abstract Keishibukuryogan is a Kampo medicine that induces vasodilation and improves the blood flow velocity in subcutaneous blood vessels. We herein report two cases in which keishibukuryogan completely diminished subcutaneous hematoma after cardiac resynchronization therapy pacemaker implantation and defibrillator battery replacement within a month. Keishibukuryogan can be a good option for treating or preventing subcutaneous hematoma after surgical procedures for devices. PMID...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
AbstractPurpose of reviewDevice-based therapy utilizing cardiac contractility modulation (CCM ™) was approved by the FDA in March 2019 for patients with moderately to severely symptomatic heart failure with reduced ejection fraction between 25 and 45% on optimal guideline-directed medical therapy in normal sinus rhythm and not a candidate for cardiac resynchronization therapy. This review explores the mechanism of action behind CCM, the most recent clinical trials, and the expansion of therapy to additional patient populations.Recent findingsThe most recent trial on CCM explored a two-lead system, which was as equall...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Authors: Martignani C, Massaro G, Diemberger I, Ziacchi M, Angeletti A, Galiè N, Biffi M PMID: 33026264 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
This article is categorized under: Cardiovascular Diseases> Computational Models Cardiovascular Diseases> Biomedical Engineering Cardiovascular Diseases> Molecular and Cellular Physiology
Source: Wiley Interdisciplinary Reviews: Systems Biology and Medicine - Category: Biomedical Science Authors: Tags: ADVANCED REVIEW Source Type: research
Authors: Czaja-Ziółkowska MZ, Wasilewski JP, Głowacki J, Wygoda Z, Gąsior M Abstract The first part of the review concerning myocardial imaging by single photon emission computed tomography (SPECT) discussed the basic aspects of interpretation of left ventricular perfusion disorders in stress and rest examination. The second part presented the interpretation of gated SPECT imaging in relation to the assessment of systolic and diastolic left ventricular functions. The third part concerns the assessment of myocardial viability and phase analysis from gated SPECT in the qualification of patients with left ventr...
Source: Polish Journal of Cardio-Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Kardiochir Torakochirurgia Pol Source Type: research
Conclusions: IAB is associated with new-onset AF and death in CRT recipients and may be helpful in the risk stratification in the context of heart failure management. Abnormal PTFV1 did not demonstrate any prognostic value.Cardiology
Source: Cardiology - Category: Cardiology Source Type: research
Conditions:   Hypotension;   Heart Failure Interventions:   Drug: Dapagliflozin;   Drug: Sacubitril-Valsartan;   Drug: Beta blocker;   Drug: Mineralocorticoid Receptor Antagonist;   Device: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator Sponsor:   Cheng-Hsin General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 2 October 2020Source: American Heart JournalAuthor(s): Jeremiah Joyce, Edward T. O'Leary, Douglas Y. Mah, David M. Harrild, Jonathan Rhodes
Source: American Heart Journal - Category: Cardiology Source Type: research
Authors: Moti H Abstract In the present paper we review data of the efficacy of CRT based on baseline QRS duration and morphology in patients with heart failure due to left ventricle systolic dysfunction. We specifically review data that analyzed men and women separately. The main findings suggest benefit of CRT in patients with baseline LBBB, but not in patients without LBBB. Benefit is directly related to QRS duration at baseline with increasing rates and magnitude of echocardiographic response ( in terms of improvement in ejection fraction and decrease un LV size) and clinical response with increasing baseline Q...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
This study sought to assess the clinical utility of ICG in comparison with that of UCG for the optimization of CRT devices.Patients who underwent CRT device implantation were retrospectively analyzed. One week after implantation, optimization of AV delay (AVD) was performed in every patient with ICG (AVD-ICG) and UCG (AVD-UCG). VV delay (VVD) was then determined according to the optimal AVD using these two methods.Forty-two patients were enrolled. Average AVD-ICG was significantly shorter than AVD-UCG (128 ± 49 versus 146 ± 41 milliseconds, P = 0.018). Five patients (12%) had the same optimized AVD with two m...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
More News: Brain | Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | China Health | Dominican Republic Health | Food and Drug Administration (FDA) | France Health | Heart | Italy Health | Medical Devices | Neurology | Neurosurgery | Orthopaedics